To: [redacted])[[redacted]@minvws.nl]
From: [redacted])
Sent: Tue 9/8/2020 7:34:20 AM
Subject: FW: Arcturus Therapeutics COVID-19 Vaccine Publication
Received: Tue 9/8/2020 7:34:20 AM
ARCTURUS_PRECLINICAL_PUBLICATION_2020.09.03.280446v1.full.pdf

tkn

Van: [redacted]@ec.europa.eu < [redacted]@ec.europa.eu>
Verzonden: dinsdag 8 september 2020 09:31
Aan: [redacted]@sozialministerium.at; [redacted]@gesundheitsministerium.gv.at; [redacted]@gesundheitsministerium.gv.at; [redacted]@bmg.gv.at; [redacted]@fagg-afmps.be; [redacted]@fagg-afmps.be; [redacted]@bda.bg; [redacted]@moh.gov.cy; [redacted]@papd.mof.gov.cy; [redacted]@phs.moh.gov.cy; [redacted]@unob.cz; [redacted]@mzcr.cz; [redacted]@mzcr.cz; [redacted]@mzcr.cz; [redacted]@bmg.bund.de; [redacted]@bmg.bund.de; [redacted]@bmg.bund.de; [redacted]@dkma.dk; [redacted]@sm.ee; [redacted]@moh.gov.gr; [redacted]@gmail.com; [redacted]@kontozamanis.gr'; [redacted]@aemps.es; [redacted]@aemps.es; [redacted]@formin.fi; [redacted]@stm.fi; [redacted]@pm.gouv.fr; [redacted]@igf.finances.gouv.fr; [redacted]@miz.hr; [redacted]@emmi.gov.hu; [redacted]@emmi.gov.hu; [redacted]@hse.ie; [redacted]@health.gov.ie; [redacted]@hse.ie; [redacted]@health.gov.ie; [redacted]@sanita.it; [redacted]@vvkt.lt; [redacted]@ms.etat.lu; [redacted]@ms.etat.lu; [redacted]@vmnvd.gov.lv; [redacted]@gov.mt; [redacted])
< [redacted]@minvws.nl>; [redacted]) < [redacted]@minvws.nl>; [redacted]@urpl.gov.pl; [redacted]@pzh.gov.pl; [redacted]@urpl.gov.pl; [redacted]@mz.gov.pl; [redacted]@infarmed.pt; [redacted]@ms.ro; [redacted]@ms.ro; [redacted]@gov.se; [redacted]@gov.si; [redacted]@gov.si; [redacted]@health.gov.sk
CC: [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu
Onderwerp: FW: Arcturus Therapeutics COVID-19 Vaccine Publication

Dear All,

Please find attached a publication issued on Friday presenting pre-clinical results of the vaccine candidate developed by Arcturus Therapeutics. The bullet points below summarise the key highlights of the publication. These findings highlight the potential of LUNAR®-COV19 to be a potent, low dose, single shot vaccine:

- A single LUNAR®-COV19 vaccination at both the 2 µg and 10 µg level doses resulted in complete protection from measurable infection and death from SARS-CoV-2 in a transgenic human ACE2 mouse challenge model, with no detectable virus present in LUNAR®-COV19 vaccinated mice;
- The data provide strong support for the immunogenicity of LUNAR®-COV19. Results demonstrate that a single vaccination in mice led to robust antibody responses, with neutralising antibody titers increasing up to day 60;
- Activation of cell mediated immunity produced a strong viral antigen specific CD8+ T lymphocyte response and a desirable Th1 dominant immune response;
- The publication: de Alwis et al., *A Single Prime Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccination Produces Protective Adaptive Immunity* is available on the *Bioarchive* website: https://www.biorxiv.org/content/10.1101/2020.09.03.280446v1

With best regards,
The EC Vaccines Team.